Vedolizumab
- Generic Name
- Vedolizumab
- Brand Names
- Entyvio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943609-66-3
- Unique Ingredient Identifier
- 9RV78Q2002
- Background
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease. α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 intera...
- Indication
Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.
- Associated Conditions
- Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis
- Conditions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Humanitas Clinical and Research Center
- Target Recruit Count
- 450
- Registration Number
- NCT06691061
- Locations
- 🇮🇹
Humanitas Research Hospital IRCSS, Mialn, Italy
EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Therakos, LLC, a Mallinckrodt Company
- Target Recruit Count
- 30
- Registration Number
- NCT06646016
Association Between Effectiveness of Mirikizumab and UC Patients with High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Showa Inan General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06626165
- Locations
- 🇯🇵
Showa Inan General Hospital, Komagane, Nagano, Japan
The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-09-24
- Target Recruit Count
- 100
- Registration Number
- NCT06609447
- Locations
- 🇨🇳
The Seventh Medical Center, PLA General Hospital, Beijing, Beijing, China
🇨🇳Chongqing General Hospital, Chongqing, Chongqing, China
🇨🇳The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
- Conditions
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT06443502
- Locations
- 🇧🇪
UZ Leuven, Leuven, Vlaams Brabant, Belgium
🇭🇷Klinika Za Djecje Bolesti Zagreb, Zagreb, Grad Zagreb, Croatia
🇮🇱Schneider Childrens Medical Center of Israel Petah Tikvah PIN, Petach Tikvah, Israel
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 396
- Registration Number
- NCT06227910
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 220
- Registration Number
- NCT06180382
- Locations
- 🇫🇷
APHP - Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris, France
🇫🇷CHU Amiens, Amiens, France
🇫🇷CHRU Lille, Lille, France
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
- Conditions
- Interventions
- Drug: antiandrogen drug treatmentDrug: ESG401Drug: VedolizumabDrug: larotinib or enttraitinibDrug: small molecule multi-target tyrosine kinase inhibitors± ChemioterapyDrug: albumin paclitaxel with platinumDrug: HR-positive groupDrug: PI3K mutant groupDrug: Homologous Recombination repair defect groupDrug: Nectin-4 ADC groupDrug: Ivoximab groupDrug: Apalolito vorellizumab group
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Peking Union Medical College
- Target Recruit Count
- 10
- Registration Number
- NCT06145308
- Locations
- 🇨🇳
Fei Ma, Beijing, Beijing, China
🇨🇳National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 65
- Registration Number
- NCT06095128
- Locations
- 🇺🇸
Digestive Health Specialsits, Dothan, Alabama, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Hoag Hospital Newport Beach, Newport Beach, California, United States
Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-11-22
- Target Recruit Count
- 334
- Registration Number
- NCT06095596
- Locations
- 🇨🇳
the Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.